Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
QIDP Designation Granted for Treatment of Cryptococcosis Provides Priority Review, Fast-Track Status and Five Additional Years of Market Exclusivity
SAN DIEGO, March 19, 2018 -- (Healthcare Sales & Marketing Network) -- Amplyx Pharmaceuticals, a compan... Biopharmaceuticals, FDA Amplyx Pharmaceuticals, Candida, Aspergillus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 19, 2018 Category: Pharmaceuticals Source Type: news
Plant-derived volatiles may serve as future antifungals
(VIB (the Flanders Institute for Biotechnology)) A research team at the VIB-KU Leuven Center for Microbiology has developed a novel screening method to identify antimicrobial properties of volatile substances. With this assay, they tested the vapour-phase-mediated activity of 175 essential oils (EOs) and 37 EO components. Approximately half of them proved active against the most drug-resistant type of Candida. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 9, 2018 Category: Biology Source Type: news
T2 Biosystems tops The Street with Q4, 2017 earnings
T2 Biosystems Inc. (NSDQ:TTOO) today reported fourth quarter and full year 2017 earnings that topped expectations on Wall Street.
The Lexington, Mass.-based company reported sales of $1.7 million for its fourth quarter, up 87% when compared with the same quarter least year. Costs for the quarter, excluding the cost of product revenue, were $9.8 million, down 16% over the previous years costs and expenses.
Sales expectations for the fourth quarter on Wall Street were $1.3 million, which the company handily topped.
For the full year, T2 Biosystems reported revenue of $4.7 million, up 15% from the previous year. Product reve...
Source: Mass Device - March 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat T2 Biosystems Inc. Source Type: news
Is a high sugar diet damaging your gut? Six signs you could have candida overgrowth
CANDIDA is a yeast that naturally exists in the mouth, gut and vagina. It isn ’t a problem until it grows and overpopulates your digestive system, which can a number of symptoms. Here are six signs you could have candida overgrowth syndrome. (Source: Daily Express - Health)
Source: Daily Express - Health - February 16, 2018 Category: Consumer Health News Source Type: news
Could a Rare, Deadly ‘ Superbug ’ Fungus Be Gaining a Foothold? Could a Rare, Deadly ‘ Superbug ’ Fungus Be Gaining a Foothold?
The Centers for Disease Control and Prevention says the number of confirmed cases of Candida auris in the U.S. has climbed from seven in 2016 to at least 200.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
WPI Biologist Reeta Rao elected a fellow of the American Academy of Microbiology
(Worcester Polytechnic Institute) Reeta Rao, a biologist at Worcester Polytechnic Institute (WPI), has been elected a fellow of the American Academy of Microbiology. She studies the biology of fungal diseases, particularly those caused by Candida, a species of fungi responsible for oral thrush, ear infections, and vaginitis, but which is also the leading cause of serious illnesses among hospitalized patients. Treating these life-threatening infections, which have a 30-50 percent mortality rate, costs more than $1 billion annually. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news
Emerging Multidrug-Resistant Candida Species Emerging Multidrug-Resistant Candida Species
Infections caused by multidrug-resistant Candida species are on the rise. How are these infections best treated?Current Opinion in Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2018 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news
New antifungal provides hope in fight against superbugs
(Case Western Reserve University) Microscopic yeast have been wreaking havoc in hospitals around the world -- creeping into catheters, ventilator tubes, and IV lines -- and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 11, 2018 Category: Infectious Diseases Source Type: news
Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin
Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel echinocandin under development for the treatment and prevention of systemic Candida infections. Preclinical studies were conducted to evaluate the metabolic stability, plasma protein binding, pharmacokinetics, toxicity, and efficacy of CD101 at various dose levels. CD101 was stable to biotransformation in rat/monkey/human liver microsomes and rat/monkey/dog/human hepatocytes. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 1, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Novel Macrocyclic Amidinoureas: Potent Non-Azole Antifungals Active against Wild-Type and Resistant Candida Species
Novelmacrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifungal agentsagainstwild-type and fluconazoleresistantCandidaspecies. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 20, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.
MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the invitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp.MK-3118 demonstrated enhanced efficacy for most C. albicans and C. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 20, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Antifungal activity of statins against Aspergillus species
The cholesterol-lowering agents known as statins have in vitro activities against human pathogenic fungi, such as Candida species, Cryptococcus neoformans, and Zygomycetes. Synergy between statins and azoles against these fungi has also been reported. We evaluated the in vitro activities of two statins, lovastatin andsimvastatin, alone and in combination with azoles and amphotericin B, against clinical isolates ofAspergillus spp. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Statins are a class of drugs widely used for lowering high cholesterol levels through their action on 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in the synthesis of cholesterol. We studied the effects of two major statins,simvastatin and atorvastatin, on five Candida species andAspergillus fumigatus. The statins strongly inhibited the growth of all species, except Candida krusei. Supplementation of Candida albicans and A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin H
Ilicicolin H is a polyketide-nonribosomal peptide synthase (NRPS)-natural product isolated from Gliocadium roseum, which exhibits potent and broad spectrum antifungal activity, with sub- μg/mL MICs against Candida spp., Aspergillus fumigatus, and Cryptococcus spp. It showed a novel mode of action, potent inhibition (IC50 = 2-3 ng/mL) of the mitochondrial cytochrome bc1 reductase, and over 1000-fold selectivity relative to rat liver cytochrome bc1 reductase. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice
The activities ofR-135853, a novel sordarin derivative that possesses a 1,4-oxazepane ring moiety, were evaluated in vitro and in vivo.R-135853 exhibited potent in vitro activities against Candida albicans (fluconazole-susceptible strains), Candida glabrata, Candida tropicalis, and Cryptococcus neoformans, with MICs at which 90% of isolates were inhibited of 0.03, 1, 0.5, and 0.5 microg/ml, respectively. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
